Search Results - "Ricós, Georgina Gener"

NPM1‐mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage by Gener‐Ricos, Georgina, Bataller, Alex, Rodriguez‐Sevilla, Juan Jose, Chien, Kelly S., Quesada, Andres E., Almanza‐Huante, Emmanuel, Hammond, Danielle, Sasaki, Koji, DiNardo, Courtney, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Issa, Ghayas C., Short, Nicholas J., Kanagal‐Shamanna, Rashmi, Kantarjian, Hagop M., Garcia‐Manero, Guillermo, Montalban‐Bravo, Guillermo

“…Introduction NPM1‐mutated (NPM1mut) myeloid neoplasms (MNs) with <20% bone marrow (BM) blasts (NPM1mut MNs<20) are uncommon, and their classification remains…”
Get full text

Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours by Almanza‐Huante, Emmanuel, Bataller, Alex, Urrutia, Samuel, Gener‐Ricos, Georgina, Briski, Robert Edward, Kanagal‐Shamanna, Rashmi, Lu, Karen H., Westin, Shannon N., Yap, Timothy A., Takahashi, Koichi, Ravandi, Farhad, Alvarado, Yesid, Kadia, Tapan, Sasaki, Koiji, Kantarjian, Hagop M., Garcia‐Manero, Guillermo

Get full text

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study by Muñoz-González, Javier I, Álvarez-Twose, Iván, Jara-Acevedo, María, Zanotti, Roberta, Perkins, Cecelia, Jawhar, Mohamad, Sperr, Wolfgang R, Shoumariyeh, Khalid, Schwaab, Juliana, Greiner, Georg, Henriques, Ana, Caldas, Carolina, Fernández-Giménez, Carlos, Sánchez-Muñoz, Laura, Mayado, Andrea, Pérez-Pons, Alba, Schmitt-Graeff, Annette, Duyster, Justus, Tanasi, Ilaria, Olivieri, Francesco, Mora-Casterá, Elvira, Luna, Irene, Senent, Leonor, Bañas, Maria-Helena, Nuñez-García, Amanda, Jurado-Chacón, Manuel, Martín-Sánchez, Guillermo, Colado, Enrique, Xicoy, Blanca, Gener-Ricós, Georgina, Gotlib, Jason, Bonadonna, Patrizia, Reiter, Andreas, Valent, Peter, García-Montero, Andrés C, Orfao, Alberto

“…Several risk stratification models have been proposed in recent years for systemic mastocytosis but have not been directly compared. Here we designed and…”
Get full text

Osteoblastic lesions in systemic mastocytosis associated with hematological malignancy by Gener Ricós, Georgina, Xicoy Cirici, Blanca, Tapia Melendo, Gustavo

Get more information

New Mutations in HFE2 and TFR2 Genes Causing Non HFE -Related Hereditary Hemochromatosis by Hernández, Gonzalo, Ferrer-Cortès, Xenia, Venturi, Veronica, Musri, Melina, Pilquil, Martin Floor, Torres, Pau Marc Muñoz, Rodríguez, Ines Hernandez, Mínguez, Maria Àngels Ruiz, Kelleher, Nicholas J, Pelucchi, Sara, Piperno, Alberto, Alberca, Esther Plensa, Ricós, Georgina Gener, Giró, Eloi Cañamero, Pérez-Montero, Santiago, Tornador, Cristian, Villà-Freixa, Jordi, Sánchez, Mayka

“…Hereditary hemochromatosis (HH) is an iron metabolism disease clinically characterized by excessive iron deposition in parenchymal organs such as liver, heart,…”
Get full text

Real-Life Experience of Use of Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia. a Single Center Experience by Pomares, Helena, Jasson, Villarreal Hernandez, Vives, Susana, Cervera, Marta, Coll, Rosa, Zamora, Lurdes, Maluquer, Clara, Ibarra, Gladys, Ribes Amoros, Julia, Gener-Ricós, Georgina, Galiano, Mercedes, Sureda, Anna, Arnan Sangerman, Montserrat

Get full text

Osteoblastic lesions in systemic mastocytosis associated with hematological malignancy by Gener Ricós, Georgina, Xicoy Cirici, Blanca, Tapia Melendo, Gustavo

Get full text

New Mutations in IHFE2/I and ITFR2/I Genes Causing Non IHFE/I-Related Hereditary Hemochromatosis by Hernández, Gonzalo, Ferrer-Cortès, Xenia, Venturi, Veronica, Musri, Melina, Pilquil, Ma, Torres, Pau Marc Muñoz, Rodríguez, Ines Hernandez, Mínguez, Maria Àngels Ruiz, Kelleher, Nicholas J, Pelucchi, Sara, Piperno, Alberto, Alberca, Esther Plensa, Ricós, Georgina Gener, Giró, Eloi Cañamero, Pérez-Montero, Santiago, Tornador, Cristian, Villà-Freixa, Jordi, Sánchez, Mayka

“…Hereditary hemochromatosis (HH) is an iron metabolism disease clinically characterized by excessive iron deposition in parenchymal organs such as liver, heart,…”
Get full text

Advances in the management of higher-risk myelodysplastic syndromes: future prospects by Gener-Ricos, Georgina, Rodriguez-Sevilla, Juan Jose, Urrutia, Samuel, Bataller, Alex, Bazinet, Alexandre, Garcia-Manero, Guillermo

“…Higher-risk myelodysplastic syndromes (HR-MDS) are defined using a number of prognostic scoring systems that include the degree of cytopenias, percentage of…”
Get full text

Germline Predisposition to Myelodysplastic Syndromes by Gener-Ricos, Georgina, Gerstein, Yoheved S., Hammond, Danielle, DiNardo, Courtney D.

“…While germline predisposition to myelodysplastic syndromes is well-established, knowledge has advanced rapidly resulting in more cases of inherited hematologic…”
Get full text

NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage by Gener-Ricos, Georgina, Bataller, Alex, Almanza-Huante, Emmanuel, Chien, Kelly S., Hammond, Danielle E., Sasaki, Koji, DiNardo, Courtney D., Kadia, Tapan M., Daver, Naval, Borthakur, Gautam, Issa, Ghayas C., Short, Nicholas J., Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo

“…Background: The most recent World Health Organization (WHO) classification has stablished NPM1-mutated myeloid neoplasms (MNs) to be acute myeloid leukemia…”
Get full text

TP53 Y220C Mutations in Patients with Myeloid Malignancies by Gener-Ricos, Georgina, Bewersdorf, Jan Philipp, Loghavi, Sanam, Goldberg, Aaron D., Famulare, Christopher, Issa, Ghayas C., Borthakur, Gautam, Kadia, Tapan M., Carter, Bing Z., Patel, Keyur P., Andreeff, Michael, Stein, Eytan M., DiNardo, Courtney D.

“…Background:TP53 gene mutations lead to inactivation of the protein p53, causing genome instability, oncogenesis, and treatment resistance conferring an…”
Get full text

Clinical Characteristics and Outcomes of Therapy-Related Chronic Myelomonocytic Leukemia: Analysis of a Large Cohort by Bataller, Alex, Gener-Ricos, Georgina, Almanza, Emmanuel, Urrutia, Samuel, Chien, Kelly S., Hammond, Danielle E., Sasaki, Koji, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Kadia, Tapan M., Kanagal-Shamanna, Rashmi, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo

“…Introduction: Therapy-related myeloid neoplasms are associated with a previous exposure to cytotoxic agents or ionizing radiation, and account for 10-20% of…”
Get full text

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma (AM) in patients with concomitant chronic lymphocytic leukemia (CLL) by Cass, Samuel, Tobin, Joshua, Seo, Yongwoo David, Gener-Ricos, Georgina, Keung, Emily Zhi-Yun, Burton, Elizabeth M., Walsh, Danielle M., Davies, Michael A., McQuade, Jennifer Leigh, Lazar, Alexander J., Hampel, Paul Joseph, Wargo, Jennifer Ann, Ferrajoli, Alessandra

“…e19511 Background: CLL is the most prevalent adult leukemia and is associated with an increased risk of melanoma. CLL alters systemic immunity and can induce…”
Get full text

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies by Gener-Ricos, Georgina, Sasaki, Koji, Loghavi, Sanam, Maiti, Abhishek, Short, Nicholas, Haddad, Fadi, Daver, Naval, Borthakur, Gautam, Ravandi, Farhad, Kantarjian, Hagop, Patel, Keyur P., Andreeff, Michael, DiNardo, Courtney D.

Get full text

Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia by Gener-Ricos, Georgina, Haddad, Fadi, Sasaki, Koji, Issa, Ghayas C., Skinner, Jeffrey, Takahashi, Koichi, Masarova, Lucia, Burger, Jan A., Borthakur, Gautam, Bose, Prithviraj, Garcia-Manero, Guillermo, Jabbour, Elias, Kantarjian, Hagop

Get full text

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes by Chien, Kelly S., Urrutia, Samuel, Li, Ziyi, Kanagal-Shamanna, Rashmi, Abdelhakeem, Ahmed, Abuasab, Tareq, Almanza, Emmanuel, Gener-Ricos, Georgina, Bataller, Alex, Bazinet, Alexandre, Montalban-Bravo, Guillermo, Short, Nicholas J., Jabbour, Elias, Kadia, Tapan M., Ravandi, Farhad, Borthakur, Gautam, Hammond, Danielle E., Swaminathan, Mahesh, Sasaki, Koji, Dong, Xiao Qin, Pierce, Sherry, Kantarjian, Hagop, Garcia-Manero, Guillermo

“…Background: Patients with myelodysplastic syndromes (MDS) undergo risk stratification with various prognostication tools, such as the International Prognostic…”
Get full text

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes by Chien, Kelly S., Urrutia, Samuel, Li, Ziyi, Kanagal-Shamanna, Rashmi, Abdelhakeem, Ahmed, Abuasab, Tareq, Almanza, Emmanuel, Gener-Ricos, Georgina, Bataller, Alex, Bazinet, Alexandre, Montalban-Bravo, Guillermo, Short, Nicholas J., Jabbour, Elias, Kadia, Tapan M., Ravandi, Farhad, Borthakur, Gautam, Hammond, Danielle E., Swaminathan, Mahesh, Sasaki, Koji, Dong, Xiao Qin, Pierce, Sherry, Kantarjian, Hagop M., Garcia-Manero, Guillermo

“…Background: Hypomethylating agents (HMA), such as decitabine, azacitidine, and oral decitabine/cedazuridine, are standard-of-care therapies for patients with…”
Get full text

Cladribine, High-Dose AraC, Plus Gemtuzumab Ozogamicin (CLAG-GO) As Frontline Intensive Therapy for Fit Patients with Core-Binding Factor Acute Myeloid Leukemia: Preliminary Results by Gener-Ricos, Georgina, Borthakur, Gautam, Sasaki, Koji, Tang, Guilin, Montalban-Bravo, Guillermo, Jabbour, Elias, Ohanian, Maro, Yilmaz, Musa, Haddad, Fadi G., Chien, Kelly S., Ishizawa, Jo, Short, Nicholas J., Maiti, Abhishek, Swaminathan, Mahesh, Garcia-Manero, Guillermo, Daver, Naval, DiNardo, Courtney D., Ravandi, Farhad, Kadia, Tapan M.

“…Background: Core-binding factor (CBF) acute myeloid leukemias (AML) are associated with favorable outcomes when treated with intensive therapy regimens,…”
Get full text

Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results by Gener-Ricos, Georgina, Haddad, Fadi G., Sasaki, Koji, Issa, Ghayas C., Skinner, Jeffrey, Masarova, Lucia, Borthakur, Gautam, Alvarado, Yesid, Garcia-Manero, Guillermo, Jabbour, Elias, Kantarjian, Hagop

“…Dasatinib is a BCR::ABL1 tyrosine kinase inhibitor approved as frontline therapy at a 100 mg daily for chronic myeloid leukemia in chronic phase (CML-CP). The…”
Get full text